Regeneron Pharmaceuticals, Inc.: PharmaVitae Report

NEW YORK, June 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Regeneron Pharmaceuticals, Inc.: PharmaVitae Report
http://www.reportlinker.com/p0885025/Regeneron-Pharmaceuticals-Inc-PharmaVitae-Report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug. Gain insight into Regeneron's strategic outlook. Analyze company sales forecasts by product. In November 2011, the FDA approved Regeneron's second drug, Eylea, for the treatment of wet AMD. Eylea garnered sales of $24.8m in Q4 2011 and $124m in Q1 2012. Approval is expected in the EU in late 2012 or early 2013. Datamonitor conducted a survey of 31 retinal specialists in the US to assess opinions of Eylea and current use of wet AMD agents. Assess Eylea's prospects in the wet AMD market, going up against Roche's Lucentis Gain insight into Regeneron's other pipeline products, including: Arcalyst for prevention of gout flares and Zaltrap for second-line colorectal cancer Benchmark Regeneron's performance against key rivals in the prescription pharmaceutical sector

ABOUT THIS REPORT•PharmaVitae Explorer database
•Chapter structure - Sales and product analysis
- Financial analysis

•Data sourcing - Analyst consensus

EXECUTIVE SUMMARY•Company introduction - Recent developments
- Corporate relationships
- Bayer
- Astellas
- Novartis
- Roche/Genentech

•Strategic overview
•SWOT analysis - Strengths
- Weaknesses
- Opportunities
- Threats


SALES AND PRODUCT ANALYSIS•Sales overview
•Product analysis - Product sales

•Eylea (intraocular affablest; VEGF Trap-Eye) - Disease background
- CATT trial
- Retinal vein occlusion
- Diabetic macular edema
- Wet AMD clinical trials
- Opinions of Eylea
- Use in retinal vein occlusion and diabetic macular edema
- BRVO trial
- DME trial
- Current use of anti-VEGF agents in RVO and DME
- Key forecasting assumptions
- CRVO
- BRVO
- DME

•Zaltrap (intravenous aflibercept; VEGF-Trap) - Colorectal cancer clinical trials
- Several factors may impact Zaltrap's uptake in the second-line setting
- Sanofi's presence in the colorectal cancer market will aid commercialization of Zaltrap
- Key forecasting assumptions

•Arcalyst (rilonacept) - Arcalyst CAPS sales to remain flat through forecast period
- Gout background
- Gout clinical trials
- Approval of Arcalyst for the prevention of gout flares appears unlikely following negative FDA panel vote

•Sarilumab (REGN88; IL-6R antibody)
•REGN727 ( SAR236553; PCSK9 antibody) - Regeneron and Sanofi have not disclosed plans for REGN727 Phase III development

•Earlier-stage products - REGN475 ( SAR164877; NGF antibody)
- REGN668 ( SAR231893; IL-4R antibody)
- REGN421 ( SAR153192; Dll4 antibody)
- REGN910 ( SAR307746; Ang2 antibody)
- REGN846
- REGN728
- REGN1033
- REGN1154

FINANCIAL ANALYSIS•Financial performance overview - Operating costs and profit analysis, 2005–11
- Operating costs and profit analysis, 2011–17

APPENDIX•References - Datamonitor reports

•Exchange rates

TABLES•Table: Regeneron R&D pipeline
•Table: Regeneron catalyst timeline
•Table: Regeneron product portfolio overview ($m), 2011–17
•Table: Regeneron/Bayer-sponsored Eylea clinical trials, ongoing
•Table: Overview of pivotal Phase III data for Eylea in wet AMD
•Table: Overview of pivotal Phase III data for Eylea and Lucentis in macular edema secondary to CRVO
•Table: Eylea US wet AMD forecast model, 2012–17
•Table: Eylea US RVO forecast model, 2012–17
•Table: Eylea US DME forecast model, 2012–17
•Table: Worldwide Eylea sales, 2012–17
•Table: Zaltrap colorectal cancer clinical trials
•Table: Summary of results from the Phase III VELOUR trial
•Table: Zaltrap sales forecast, seven major markets ($m), 2012–17
•Table: Arcalyst gout Phase III trials
•Table: Summary of results from the Phase III PRE-SURGE trials
•Table: Sarilumab trials
•Table: Summary of results from the Phase IIb portion of the MOBILITY trial
•Table: REGN727 trials
•Table: Regeneron operating revenue/cost analysis ($m), 2005–11
•Table: Regeneron operating revenue/cost analysis ($m), 2011–17
•Table: Exchange rates, 2011


FIGURES•Figure: PharmaVitae Explorer
•Figure: Regeneron prescription pharmaceutical performance, sales ($m) and growth rate (%), 2011–17
•Figure: Regeneron sales ($m), 2011–17
•Figure: In October 2011 (immediately prior to the approval of Eylea), what percentage of your treated wet AMD patients were receiving the following treatments?
•Figure: Following the 2-year results of the CATT trial, how do you view Avastin versus Lucentis in terms of efficacy/safety?
•Figure: Based on your knowledge of the three anti-VEGF agents, please rate them on a scale from 1 to 5 on the following attributes, where 1=poor and 5=excellent.
•Figure: Of the patients to whom you have administered Eylea, what percentage falls into each of the following categories? (Weighted average)
•Figure: So far this year, what percentage of your newly diagnosed patients received the following agents as their first-line therapy? Three years from now, what percentage of your newly diagnosed patients do you expect will receive the following agents as their first-line therapy?
•Figure: Of your patients failing their first-line therapy, what percentage do you expect will receive Avastin, Lucentis, or Eylea as a second-line therapy?
•Figure: Of your CRVO/BRVO/DME patients, what percentages are currently treated with the following?
•Figure: Regeneron operating/cost performance ($m), 2005–17

Companies mentioned

Bunzl plc, BWT AG, Hutchison 3G UK Limited, Ipsen S.A., Merck KGaA, QLT Inc., VINCI

To order this report:
: Regeneron Pharmaceuticals, Inc.: PharmaVitae Report

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker